Universal Access to HIV Treatment versus Universal 'Test and Treat': Transmission, Drug Resistance & Treatment Costs

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Wagner, Bradley G ^a   Blower, Sally ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; EPIDEMIC; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HIV TEST; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MATHEMATICAL MODEL; PREDICTION; RISK ASSESSMENT; SURVIVAL TIME; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

CD4-POSITIVE T-LYMPHOCYTES; COMMUNICABLE DISEASE CONTROL; DRUG RESISTANCE, VIRAL; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HEALTH SERVICES NEEDS AND DEMAND; HIV INFECTIONS; HUMANS; MODELS, THEORETICAL; PREVALENCE; SOUTH AFRICA; WORLD HEALTH ORGANIZATION;

EID: 84866006208     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041212     Document Type: Article

References (23)

1. Cohen MS, Mastro TD, Cates W, (2009) Universal voluntary HIV testing and immediate antiretroviral therapy. Lancet 373: 1077 author reply 1080-1071.
2. Dieffenbach CW, Fauci AS, (2009) Universal voluntary testing and treatment for prevention of HIV transmission. JAMA 301: 2380-2382.
3. El-Sadr WM, Affrunti M, Gamble T, Zerbe A, (2010) Antiretroviral therapy: a promising HIV prevention strategy? J Acquir Immune Defic Syndr 55 Suppl 2: S116-121.
4. Garnett GP, Baggaley RF, (2009) Treating our way out of the HIV pandemic: could we, would we, should we? Lancet 373: 9-11.
5. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG, (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57.
6. Lima VD, Johnston K, Hogg RS, Levy AR, Harrigan PR, et al. (2008) Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis 198: 59-67.
7. Montaner JSG, Hogg R, Wood E, Kerr T, Tyndall M, et al. (2006) The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 368: 531-536.
8. Wagner BG, Kahn JS, Blower S, (2010) Should we try to eliminate HIV epidemics by using a 'Test and Treat' strategy? AIDS 24: 775-776.
9. Wagner B, Blower S, (2010) Costs of eliminating HIV in South Africa have been underestimated. Lancet 376: 953-954.
10. Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, et al. (2012) Expanding ART for Treatment and Prevention of HIV in South Africa: Estimated Cost and Cost-Effectiveness 2011-2050. PLoS ONE 7: e30216.
11. Dodd PJ, Garnett GP, Hallett TB, (2010) Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 24: 729-735.
12. Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S, (2010) Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science 327: 697-701.
13. Blower SM, Gershengorn HB, Grant RM, (2000) A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 287: 650-654.
14. Dodd PJ, Garnett GP, Hallett TB, (2009) Examining the Promise of HIV Elimination by 'Test and Treat' in Hyper-Endemic Settings. pp. 1-44.
15. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, et al. (2011) Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 155: 209-216.
16. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
17. Velasco-Hernandez JX, Gershengorn HB, Blower SM, (2002) Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2: 487-493.
18. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med.
19. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
20. Gray R, Kigozi G, Kong X, Ssempiija V, Makumbi F, et al. (2012) The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS 26: 609-615.
21. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369: 657-666.
22. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012) Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med.
23. Statistics South Africa (2010) Mid-year population estimates 2010. http://www.statssa.gov.za/publications/P0302/P03022010.pdf. Accessed 2012 April 2.